0001211583
false
0001211583
2023-08-03
2023-08-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 3, 2023
FENNEC PHARMACEUTICALS
INC.
(Exact name of registrant as specified in its charter)
001-32295
(Commission File Number)
British Columbia, Canada |
|
20-0442384 |
(State or other jurisdiction of
incorporation) |
|
(I.R.S. Employer Identification No.) |
PO Box 13628, 68 TW Alexander Drive,
Research Triangle Park, NC |
|
27709 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (919) 636-4530
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Title of each class |
Trading symbol(s) |
Name of each exchange on which
registered |
Common |
FENC, FRX |
Nasdaq, TSX |
Item 2.02. |
Results of Operations and Financial Condition. |
On August 3, 2023, Fennec
Pharmaceuticals Inc. issued a news release announcing the first-quarter financial results for the period ended June 30, 2023. A copy of
the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained
in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for
the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference
into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form
8-K.
Item 9.01 |
Financial Statements and Exhibits. |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
FENNEC PHARMACEUTICALS INC. |
|
|
|
|
|
|
Date August 4, 2023 |
By: |
/s/ Robert Andrade |
|
|
Robert Andrade |
|
|
Chief Financial Officer |
Exhibit 99.1
FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER
2023
FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
~ Growing Physician Awareness and Usage of
PEDMARK® Drove Quarterly Revenue Growth of 98% ~
~Fennec Expands Leadership Team with the Appointment
of Adrian Haigh as Chief Operating Officer ~
~ Management to Host Conference Call Today
at 8:30 a.m. ET ~
Research Triangle Park, NC, August 3, 2023
– Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today reported
its financial results for the second quarter ended June 30, 2023 and provided a business update.
“During the second quarter, we continued
to make strong progress with the U.S. commercial launch of PEDMARK®, delivering net revenue of $3.3 million, which is
a 98% increase in net revenue over the first quarter of 2023. These results reflect strong growth in patient starts and new account orders,”
said Rosty Raykov, chief executive officer of Fennec Pharmaceuticals. “Further, we are delighted to announce the appointment of
Adrian Haigh, a Fennec board member since 2014, to the position of Chief Operating Officer. Adrian brings significant experience in evaluating
business development opportunities and preparing global commercial operations, and we are pleased to have him on our leadership team.”
Appointment of Adrian Haigh as Chief Operating
Officer
Fennec has expanded
its leadership team with the appointment of Adrian Haigh as Chief Operating Officer. Adrian has been a board member of Fennec
since 2014 and with his appointment to the management team of Fennec will step down as board member. Adrian recently retired from PTC
Therapeutics where his last role was Senior Vice President and Head of International. Previously, Mr. Haigh served as Chief Operating
Officer at Gentium GmbH where he built and managed the company’s commercial and medical affairs organization and was also responsible
for business development, playing a pivotal role in the sale of Gentium to Jazz Pharmaceuticals for $1 billion.
"I am delighted
to join Fennec at this critical point in the commercial evolution of the company and to be part of the leadership team that is evaluating
all options for PEDMARK® worldwide," said Adrian Haigh. “Further, having been part of Fennec’s board
for nearly a decade, I will continue Fennec's unrelenting commitment to enabling rapid access to PEDMARK® to all eligible
patients as hearing loss from cisplatin chemotherapy is a permanently disabling and devastating side effect of cancer treatment.”
Upcoming Investor Conference
| · | Fennec
management will be participating at the 2023 Wedbush PacGrow Healthcare Conference on August
8-9, 2023, at the Lotte Palace Hotel in New York, NY. |
Financial Results for the Second Quarter
2023
| · | Cash
Position – Cash and cash equivalents were $15.0 million on June 30, 2023.
The decrease in cash and cash equivalents between June 30, 2023, and December 31, 2022, is
the result of cash outlays for operating expenses related to the promotion and marketing
of PEDMARK®, small amounts of research and development and general and administrative
expenses, which were offset by cash inflows primarily from product sales of $2.1 million.
We anticipate that our cash, cash equivalents and investment securities as of June 30, 2023
will be sufficient to fund our planned operations for at least the next twelve months. |
| · | Net
Sales – The company recorded net product sales of $3.3 million in the second quarter
of 2023 compared to net product sales of $1.7 million in the first quarter of 2023. The Company
had gross profit of $3.2 million for the second quarter of 2023. The increase in sales reflects
strong growth in new patient starts and account adoption. |
| · | Research
and Development (R&D) Expenses – Research and development expenses
decreased by $1.1 million for the three months ended June 30, 2023, compared to the same
period in 2022. The Company’s research and development activities for the quarter ended
June 30, 2023 consisted of costs associated with investigator initiated clinical trials.
During the same period in 2022 and prior to approval of PEDMARK®, manufacturing
costs pertaining to PEDMARK® were expensed to R&D expense in the period
incurred, and following approval are reflected in inventory. |
| · | Selling
and Marketing Expenses – Selling and marketing expenses include remuneration of
our sales and marketing employees, dollars spent on marketing campaigns (sponsorships, trade
shows, presentations, etc.), and any activities to support marketing and sales activities.
Selling and marketing expenses for the second quarter of 2023 were $2.3 million compared
to $2.5 million in the first quarter of 2023. |
| · | General
and Administrative (G&A) Expenses – For the three month period ended June
30, 2023, G&A expenses increased by $1.6 million over the same period in 2022. Further,
G&A expenses increased by $1.1 million compared to the first quarter of 2023. The increase
in G&A was primarily because of increases in non-cash employee remuneration which accounted
for $1.5 million of the increase over same period in 2022. |
| · | Net
Loss – Net loss for the quarter ended June 30, 2023, was $5.4 million ($0.21
per share), compared to $5.1 million ($0.19 per share) for the same period in 2022. |
Q2 2023 CONFERENCE
CALL INFORMATION
The
Company will host a conference call today, August 3, at 8:30 a.m. ET, to discuss the Company’s financial results from the second
quarter, ended June 30, 2023, and provide a business outlook for the remainder of 2023.
To access
the conference call, please register at: https://register.vevent.com/register/BIda2814a842e34d0d825731a73c51d74d. Upon registration,
a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.fennepharma.com and
proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s
website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen
to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
Financial Update
The selected financial data presented below is
derived from our unaudited condensed consolidated financial statements, which were prepared in accordance with U.S. generally accepted
accounting principles. The complete unaudited condensed consolidated financial statements for the period ended June 30, 2023, and management's
discussion and analysis of financial condition and results of operations will be available via www.sec.gov and www.sedar.com. All
values are presented in thousands unless otherwise noted.
Unaudited Condensed Consolidated
Statements of Operations:
(U.S. Dollars in thousands except per share amounts)
| |
Three Months Ended | |
| |
June 30, | | |
June 30, | |
| |
2023 | | |
2022 | |
Revenue | |
| | | |
| | |
PEDMARK product sales, net | |
$ | 3,325 | | |
$ | — | |
Cost of products sold | |
| (148 | ) | |
| — | |
Gross profit | |
| 3,177 | | |
| — | |
| |
| | | |
| | |
Operating expenses: | |
| | | |
| | |
Research and development | |
| 8 | | |
| 1,131 | |
Selling and marketing | |
| 2,340 | | |
| — | |
General and administrative | |
| 5,495 | | |
| 3,878 | |
| |
| | | |
| | |
Total operating expenses | |
| 7,843 | | |
| 5,009 | |
Loss from operations | |
| (4,666 | ) | |
| (5,009 | ) |
| |
| | | |
| | |
Other (expense)/income | |
| | | |
| | |
Unrealized foreign exchange loss | |
| 5 | | |
| 1 | |
Amortization expense | |
| (73 | ) | |
| (8 | ) |
Unrealized loss on securities | |
| — | | |
| (8 | ) |
Interest income | |
| 115 | | |
| 9 | |
Interest expense | |
| (825 | ) | |
| (57 | ) |
Total other (expense)/income | |
| (778 | ) | |
| (63 | ) |
| |
| | | |
| | |
Net loss | |
$ | (5,444 | ) | |
$ | (5,072 | ) |
| |
| | | |
| | |
Basic net loss per common share | |
$ | (0.21 | ) | |
$ | (0.19 | ) |
Diluted net loss per common share | |
$ | (0.21 | ) | |
$ | (0.19 | ) |
Weighted-average number of common shares outstanding basic | |
| 26,458 | | |
| 26,052 | |
Weighted-average number of common shares outstanding diluted | |
| 26,458 | | |
| 26,052 | |
Fennec Pharmaceuticals Inc.
Balance Sheets
(U.S. Dollars in thousands)
| |
Unaudited | | |
Audited | |
| |
June 30, | | |
December 31, | |
| |
2023 | | |
2022 | |
Assets | |
| | | |
| | |
| |
| | | |
| | |
Current assets | |
| | | |
| | |
Cash and cash equivalents | |
$ | 14,958 | | |
$ | 23,774 | |
Accounts receivable, net | |
| 2,445 | | |
| 1,545 | |
Prepaid expenses | |
| 457 | | |
| 770 | |
Inventory | |
| 1,439 | | |
| 576 | |
Other current assets | |
| 32 | | |
| 63 | |
Total current assets | |
| 19,331 | | |
| 26,728 | |
| |
| | | |
| | |
Non-current assets | |
| | | |
| | |
Deferred issuance cost, net amortization | |
| 106 | | |
| 211 | |
Total non-current assets | |
| 106 | | |
| 211 | |
Total assets | |
$ | 19,437 | | |
$ | 26,939 | |
| |
| | | |
| | |
Liabilities and shareholders’ (deficit) equity | |
| | | |
| | |
| |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 3,005 | | |
$ | 2,390 | |
Accrued liabilities | |
| 773 | | |
| 2,219 | |
Total current liabilities | |
| 3,778 | | |
| 4,609 | |
| |
| | | |
| | |
Long term liabilities | |
| | | |
| | |
Term loan | |
| 25,000 | | |
| 25,000 | |
PIK interest | |
| 707 | | |
| 260 | |
Debt discount | |
| (321 | ) | |
| (361 | ) |
Total long term liabilities | |
| 25,386 | | |
| 24,899 | |
Total liabilities | |
| 29,164 | | |
| 29,508 | |
| |
| | | |
| | |
Shareholders’(deficit) equity: | |
| | | |
| | |
Common stock, no par value; unlimited shares authorized; 26,411
shares issued and outstanding (2022 -26,361) | |
| 143,345 | | |
| 142,591 | |
Additional paid-in capital | |
| 60,381 | | |
| 56,797 | |
Accumulated deficit | |
| (214,696 | ) | |
| (203,200 | ) |
Accumulated other comprehensive income | |
| 1,243 | | |
| 1,243 | |
Total shareholders’ (deficit) equity | |
| (9,727 | ) | |
| (2,569 | ) |
Total liabilities and shareholders’ (deficit) equity | |
$ | 19,437 | | |
$ | 26,939 | |
Working Capital
Working capital | |
Fiscal Period Ended | |
Selected Asset and Liability Data: | |
June 30, 2023 | | |
December
31, 2022 | |
(U.S. Dollars in thousands) | |
| | | |
| | |
Cash and equivalents | |
$ | 14,958 | | |
$ | 23,774 | |
Other current assets | |
| 4,373 | | |
| 2,954 | |
Current liabilities | |
| (3,778 | ) | |
| (4,608 | ) |
Working capital | |
$ | 15,553 | | |
$ | 22,120 | |
| |
| | | |
| | |
Selected Equity: | |
| | | |
| | |
Common stock and additional paid in capital | |
| 203,726 | | |
| 199,388 | |
Accumulated deficit | |
| (214,696 | ) | |
| (203,200 | ) |
Shareholders’ (deficit) equity | |
| (9,727 | ) | |
| (2,569 | ) |
About
Cisplatin-Induced Ototoxicity
Cisplatin
and other platinum compounds are essential chemotherapeutic agents for the treatment of many pediatric malignancies. Unfortunately, platinum-based
therapies can cause ototoxicity, or hearing loss, which is permanent, irreversible, and particularly harmful to the survivors of pediatric
cancer.i
The incidence
of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids or cochlear
implants, which can be helpful for some, but do not reverse the hearing loss and can be costly over time.ii
Infants and young children that are affected by ototoxicity at critical stages of development lack speech and language development
and literacy, and older children and adolescents often lack social-emotional development and educational achievement.iii
PEDMARK® (sodium thiosulfate injection)
PEDMARK® is the first and only
U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment
in pediatric patients with localized, non-metastatic, solid tumors. It is a unique formulation of sodium thiosulfate in single-dose,
ready-to-use vials for intravenous use in pediatric patients. PEDMARK is also the only therapeutic agent with proven efficacy and safety
data with an established dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG)
Protocol ACCL0431 and SIOPEL 6.
In the
U.S. and Europe, it is estimated that, annually, more than 10,000 children may receive platinum-based chemotherapy. The incidence of
ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently
no established preventive agent for this hearing loss and only expensive, technically difficult, and sub-optimal cochlear (inner ear)
implants have been shown to provide some benefit. Infants and young children that suffer ototoxicity at critical stages of development
lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.
PEDMARK
has been studied by co-operative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, COG ACCL0431 and SIOPEL
6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin
therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma,
medulloblastoma, and other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.
Indications
and Usage
PEDMARK®
(sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month
of age and older with localized, non-metastatic solid tumors.
Limitations of Use
The safety and efficacy of PEDMARK have not been
established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when
administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.
Important Safety Information
PEDMARK is contraindicated in patients with history
of a severe hypersensitivity to sodium thiosulfate or any of its components.
Hypersensitivity reactions occurred in 8% to
13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate
care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration
of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic
symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.
PEDMARK is not indicated for use in pediatric
patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers.
Hypernatremia occurred in 12% to 26% of patients
in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3
or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium levels at baseline and as clinically indicated. Withhold
PEDMARK in patients with baseline serum sodium greater than 145 mmol/L.
Monitor for signs and symptoms of hypernatremia
and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73m2.
Administer antiemetics prior to each PEDMARK
administration. Provide additional antiemetics and supportive care as appropriate.
The most common adverse reactions (≥25% with
difference between arms of >5% compared to cisplatin alone) in SIOPEL 6 were vomiting, nausea, decreased hemoglobin, and hypernatremia.
The most common adverse reaction (≥25% with difference between arms of >5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.
Please see full Prescribing Information for PEDMARK®
at: www.PEDMARK.com.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty
pharmaceutical company focused on the development and commercialization of PEDMARK® and PedmarqsiTM to
reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and
European Commission Marketing Authorization in June 2023 for Pedmarqsi. PEDMARK has received Orphan Drug Exclusivity in the U.S. for
seven years of market protection and Pedmarqsi has received Pediatric Use Marketing Authorization in Europe which includes
eight years plus two years of data and market protection. Fennec has a license agreement with Oregon Health and Science University (OHSU)
for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including
the reduction of risk of ototoxicity induced by platinum chemotherapy, in humans. For more information, please visit www.fennecpharma.com.
Forward Looking Statements
Except for historical information described
in this press release, all other statements are forward-looking. Words such as “believe,” “anticipate,” “plan,”
“expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms,
and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about
our business strategy, timeline, and other goals, plans and prospects, including our commercialization plans respecting PEDMARK®,
the market opportunity for and market impact of PEDMARK®, its potential impact on patients and anticipated benefits associated with
its use, and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks
and uncertainties inherent in the Company’s business that could cause actual results to vary, including the risks and uncertainties
that regulatory and guideline developments may change, scientific data and/or manufacturing capabilities may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient
settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease,
such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Company’s
patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s
products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues
will not be sufficient to fund further development and clinical studies, our ability to obtain necessary capital when needed on acceptable
terms or at all, the Company may not meet its future capital requirements in different countries and municipalities, and other risks
detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on
Form 10-K for the year ended December 31, 2022. Fennec disclaims any obligation to update these forward-looking statements except as
required by law.
For a more detailed discussion of related
risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.
PEDMARK® and Fennec®
are registered trademarks of Fennec Pharmaceuticals Inc.
©2023 Fennec Pharmaceuticals Inc. All rights
reserved.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
(919) 246-5299
Media:
Elixir Health Public Relations
Lindsay Rocco
(862) 596-1304
lrocco@elixirhealthpr.com
i
Rybak L. Mechanisms of Cisplatin Ototoxicity and Progress in Otoprotection. Current Opinion in Otolaryngology & Head and Neck Surgery.
2007, Vol. 15: 364-369.
ii
Landier W. Ototoxicity and Cancer Therapy. Cancer. June 2016 Vol. 122, No.11: 1647-1658.
iii
Bass JK, Knight KR, Yock TI, et al. Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report
from the Children's Oncology Group. Pediatric Blood & Cancer. 2016 Jul;63(7):1152-1162.
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Fennec Pharmaceuticals (NASDAQ:FENC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fennec Pharmaceuticals (NASDAQ:FENC)
Historical Stock Chart
From Sep 2023 to Sep 2024